Renal Cancer
Cost-Effectiveness Analysis of Lenvatinib plus Pembrolizumab or Everolimus as First-Line Treatment for Advanced Renal Cell Carcinoma.
December 11, 2024
Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma.
December 10, 2024
Diagnostic and prognostic potential of FBXO8 expression in kidney renal clear cell carcinoma and its regulation of renal adenocarcinoma cells.
December 10, 2024
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study.
December 10, 2024
Increased spatial coupling of integrin and collagen IV in the immunoresistant clear-cell renal-cell carcinoma tumor microenvironment.
December 9, 2024
Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?
December 6, 2024
Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical Trials.
December 4, 2024
Validation of Prognostic Models for Renal Cell Carcinoma Recurrence, Cancer Specific Mortality and All-Cause Mortality.
December 4, 2024
Renal cell carcinoma with inferior vena cava thrombus: Survival and prognostic factors in surgically treated patients.
December 3, 2024
STAT2/SLC27A3/PINK1-Mediated Mitophagy Remodeling Lipid Metabolism Contributes to Pazopanib Resistance in Clear Cell Renal Cell Carcinoma.
December 2, 2024
Late Survival and Long-Term Follow-Up After Radical Resection of Advanced Renal Cell Carcinoma With Associated Venous Tumor Thrombus.
December 2, 2024
Comparison of outcomes between single-port and multi-port robotic radical nephrectomy.
November 29, 2024